Background: Abiraterone acetate is an androgen-receptor pathway inhibitor commonly used for treatment of metastatic prostate cancer. The levels of androgens during treatment with abiraterone acetate with prednisone (AAP) are lower than those achieved by androgen-deprivation therapy only, potentially resulting in a high risk of skeletal muscle loss. Methods: The cohort included 43 patients treated with AAP for metastatic hormone-sensitive prostate cancer or metastatic castration-resistant prostate cancer. To detect and quantify sarcopenia, we utilized standard computer tomography (CT) imaging. Skeletal muscle mass index (SMI) was evaluated by assessing two adjacent axial sections at the level of the L3 vertebra. Results: Sarcopenia at the time of AAP initiation was present in 72.1% of patients. Body mass index (BMI) was inversely associated with the presence of sarcopenia at the time of AAP initiation. There was a statistically significant decrease in SMI over AAP treatment. Age > 75 years and the absence of previous radiotherapy were associated with a higher rate of SMI decrease during AAP therapy. Overall and progression-free survival was not significantly associated with SMI decrease during AAP therapy. Conclusions: SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy.

ANOVA CRO Prague Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Oncology 1st Faculty of Medicine Thomayer University Hospital Prague Czech Republic

Department of Oncology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Oncology 2nd Faculty of Medicine Motol University Hospital Prague Czech Republic

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Urology 1st Faculty of Medicine Central Military Hospital Prague Czech Republic

Department of Urology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Cruz-Jentoft A. J., Bahat G., Bauer J., et al. Sarcopenia: Revised European Consensus on Definition and Diagnosis. Age and Ageing . 2019;48(1):16–31. doi: 10.1093/ageing/afy169. PubMed DOI PMC

Anjanappa M., Corden M., Green A., et al. Sarcopenia in Cancer: Risking More Than Muscle Loss. Technical Innovations & Patient Support in Radiation Oncology . 2020;16:50–57. doi: 10.1016/j.tipsro.2020.10.001. PubMed DOI PMC

Smith M. R., Saad F., Egerdie B., et al. Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer. Journal of Clinical Oncology . 2012;30(26):3271–3276. doi: 10.1200/JCO.2011.38.8850. PubMed DOI PMC

Galvão D. A., Spry N. A., Taaffe D. R., et al. Changes in Muscle, Fat and Bone Mass After 36 Weeks of Maximal Androgen Blockade for Prostate Cancer. BJU International . 2008;102(1):44–47. doi: 10.1111/j.1464-410X.2008.07539.x. PubMed DOI

Chang D., Joseph D. J., Ebert M. A., et al. Effect of Androgen Deprivation Therapy on Muscle Attenuation in Men With Prostate Cancer. Journal of Medical Imaging and Radiation Oncology . 2014;58(2):223–228. doi: 10.1111/1754-9485.12124. PubMed DOI

Attard G., Belldegrun A. S., de Bono J. S. Selective Blockade of Androgenic Steroid Synthesis by Novel Lyase Inhibitors as a Therapeutic Strategy for Treating Metastatic Prostate Cancer. BJU International . 2005;96(9):1241–1246. doi: 10.1111/j.1464-410X.2005.05821.x. PubMed DOI

Attard G., Reid A. H. M., Yap T. A., et al. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. Journal of Clinical Oncology . 2008;26(28):4563–4571. doi: 10.1200/JCO.2007.15.9749. PubMed DOI

Schakman O., Kalista S., Barbé C., Loumaye A., Thissen J. P. Glucocorticoid-Induced Skeletal Muscle Atrophy. The International Journal of Biochemistry & Cell Biology . 2013;45(10):2163–2172. doi: 10.1016/j.biocel.2013.05.036. PubMed DOI

Gomez‐Perez S. L., Haus J. M., Sheean P., et al. Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed Tomography Image: A Step-by-step Guide for Clinicians Using National Institutes of Health ImageJ. Journal of Parenteral and Enteral Nutrition . 2016;40(3):308–318. doi: 10.1177/0148607115604149. PubMed DOI PMC

Prado C. M. M., Lieffers J. R., McCargar L. J., et al. Prevalence and Clinical Implications of Sarcopenic Obesity in Patients With Solid Tumours of the Respiratory and Gastrointestinal Tracts: A Population-Based Study. The Lancet Oncology . 2008;9(7):629–635. doi: 10.1016/S1470-2045(08)70153-0. PubMed DOI

Xu M. C., Huelster H. L., Hatcher J. B., et al. Obesity is Associated With Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer. The Journal of Urology . 2021;205(3):800–805. doi: 10.1097/ju.0000000000001428. PubMed DOI PMC

Iwamoto G., Kawahara T., Miyai T., et al. A Lower Psoas Muscle Index Predicts a Poorer Prognosis in Metastatic Hormone‐Naïve Prostate Cancer. BJUI Compass . 2021;2(1):39–45. doi: 10.1002/bco2.36. PubMed DOI PMC

Ikeda T., Ishihara H., Iizuka J., et al. Prognostic Impact of Sarcopenia in Patients With Metastatic Hormone-Sensitive Prostate Cancer. Japanese Journal of Clinical Oncology . 2020;50(8):933–939. doi: 10.1093/jjco/hyaa045. PubMed DOI

Kovač M. B., Pavlin T., Čavka L., et al. The Trajectory of Sarcopenia Following Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Geriatric Oncology . 2023;14(7):p. 101594. doi: 10.1016/j.jgo.2023.101594. PubMed DOI

Papadopoulos E., Wong A. K. O., Law S. H. C., et al. The Impact of Sarcopenia on Clinical Outcomes in Men With Metastatic Castrate-Resistant Prostate Cancer. PLoS One . 2023;18(6):p. e0286381. doi: 10.1371/journal.pone.0286381. PubMed DOI PMC

Hartrampf P. E., Mihatsch P. W., Seitz A. K., et al. Elevated Body Mass Index is Associated With Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy. Journal of Nuclear Medicine . 2023;64(8):1272–1278. doi: 10.2967/jnumed.122.265379. PubMed DOI

Khan M., Parshad S., Naimi M. F., et al. Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy. Clinical Genitourinary Cancer . 2023;21(4):e228–e235.e1. doi: 10.1016/j.clgc.2023.01.009. PubMed DOI

Cushen S. J., Power D. G., Murphy K. P., et al. Impact of Body Composition Parameters on Clinical Outcomes in Patients With Metastatic Castrate-Resistant Prostate Cancer Treated With Docetaxel. Clinical Nutrition ESPEN . 2016;13:e39–e45. doi: 10.1016/j.clnesp.2016.04.001. PubMed DOI

Ohtaka A., Aoki H., Nagata M., et al. Sarcopenia is a Poor Prognostic Factor of Castration-Resistant Prostate Cancer Treated With Docetaxel Therapy. Prostate International . 2019;7(1):9–14. doi: 10.1016/j.prnil.2018.04.002. PubMed DOI PMC

Stangl-Kremser J., Suarez‐Ibarrola R., Andrea D. D., et al. Assessment of Body Composition in the Advanced Stage of Castration-Resistant Prostate Cancer: Special Focus on Sarcopenia. Prostate Cancer and Prostatic Diseases . 2020;23(2):309–315. doi: 10.1038/s41391-019-0186-6. PubMed DOI

Sheikhbahaei S., Reyes D. K., Rowe S. P., Pienta K. J. CT‐Based Assessment of Body Composition Following Neoadjuvant Chemohormonal Therapy in Patients With Castration‐Naïve Oligometastatic Prostate Cancer. The Prostate . 2021;81(2):127–134. doi: 10.1002/pros.24088. PubMed DOI PMC

Chiang P.-K., Tsai W.-K., Chiu A. W.-H., Lin J.-B., Yang F.-Y., Lee J. Muscle Loss During Androgen Deprivation Therapy is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer. Frontiers in Oncology . 2021;11:p. 722652. doi: 10.3389/fonc.2021.722652. PubMed DOI PMC

de Pablos-Rodríguez P., del Pino-Sedeño T., Infante-Ventura D., et al. Prognostic Impact of Sarcopenia in Patients With Advanced Prostate Carcinoma: A Systematic Review. Journal of Clinical Medicine . 2022;12(1):p. 57. doi: 10.3390/jcm12010057. PubMed DOI PMC

Mason R. J., Boorjian S. A., Bhindi B., et al. The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy. Clinical Genitourinary Cancer . 2018;16(3):e629–e636. doi: 10.1016/j.clgc.2017.11.003. PubMed DOI

Hiroshige T., Ogasawara N., Kumagae H., et al. Sarcopenia and the Therapeutic Effects of Androgen Receptor-Axis-Targeted Therapies in Patients With Castration-Resistant Prostate Cancer. In Vivo . 2023;37(3):1266–1274. doi: 10.21873/invivo.13204. PubMed DOI PMC

Fischer S., Clements S., McWilliam A., et al. Influence of Abiraterone and Enzalutamide on Body Composition in Patients With Metastatic Castration-Resistant Prostate Cancer. Cancer Treatment and Research Communications . 2020;25:p. 100256. doi: 10.1016/j.ctarc.2020.100256. PubMed DOI

Pezaro C., Mukherji D., Tunariu N., et al. Sarcopenia and Change in Body Composition Following Maximal Androgen Suppression With Abiraterone in Men With Castration-Resistant Prostate Cancer. British Journal of Cancer . 2013;109(2):325–331. doi: 10.1038/bjc.2013.340. PubMed DOI PMC

Blow T. A., Murthy A., Grover R., et al. Profiling of Skeletal Muscle and Adipose Tissue Depots in Men With Advanced Prostate Cancer Receiving Different Forms of Androgen Deprivation Therapy. European Urology Open Science . 2023;57:1–7. doi: 10.1016/j.euros.2023.09.004. PubMed DOI PMC

Lopez P., Newton R. U., Taaffe D. R., Winters-Stone K., Galvão D. A., Buffart L. M. Moderators of Resistance-Based Exercise Programs’ Effect on Sarcopenia-Related Measures in Men With Prostate Cancer Previously or Currently Undergoing Androgen Deprivation Therapy: An Individual Patient Data Meta-Analysis. Journal of Geriatric Oncology . 2023;14(5):p. 101535. doi: 10.1016/j.jgo.2023.101535. PubMed DOI

Vashi P. G., Gorsuch K., Wan L., Hill D., Block C., Gupta D. Sarcopenia Supersedes Subjective Global Assessment as a Predictor of Survival in Colorectal Cancer. PLoS One . 2019;14(6):p. e0218761. doi: 10.1371/journal.pone.0218761. PubMed DOI PMC

Lee J. H., Jee B. A., Kim J. H., et al. Prognostic Impact of Sarcopenia in Patients With Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel) . 2021;13(24):p. 6345. doi: 10.3390/cancers13246345. PubMed DOI PMC

Ashton E., Arrondeau J., Jouinot A., et al. Impact of Sarcopenia Indexes on Survival and Severe Immune Acute Toxicity in Metastatic Non-Small Cell Lung Cancer Patients Treated With PD-1 Immune Checkpoint Inhibitors. Clinical Nutrition . 2023;42(6):944–953. doi: 10.1016/j.clnu.2023.03.023. PubMed DOI

Hilmi M., Jouinot A., Burns R., et al. Body Composition and Sarcopenia: The Next-Generation of Personalized Oncology and Pharmacology? Pharmacology & Therapeutics . 2019;196:135–159. doi: 10.1016/j.pharmthera.2018.11.010. PubMed DOI

Luo L., Shen X., Fang S., et al. Sarcopenia as a Risk Factor of Progression-Free Survival in Patients With Metastases: A Systematic Review and Meta-Analysis. BMC Cancer . 2023;23(1):p. 127. doi: 10.1186/s12885-023-10582-2. PubMed DOI PMC